WTA
REGN icon

Washington Trust Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Washington Trust Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.2M Sell
28,735
-689
-2% -$527K 1.8% 14
2025
Q4 		$22.7M Sell
29,424
-301
-1% -$204K 1.74% 16
2025
Q3 		$16.7M Sell
29,725
-236
-0.8% -$133K 1.27% 22
2025
Q2 		$15.7M Buy
29,961
+435
+1% +$243K 1.28% 24
2025
Q1 		$18.7M Buy
29,526
+236
+0.8% +$162K 1.66% 20
2024
Q4 		$20.9M Sell
29,290
-89
-0.3% -$74.7K 1.74% 17
2024
Q3 		$30.9M Sell
29,379
-106
-0.4% -$118K 2.66% 12
2024
Q2 		$31M Sell
29,485
-1,211
-4% -$1.17M 2.85% 10
2024
Q1 		$29.5M Sell
30,696
-1,529
-5% -$1.45M 2.71% 11
2023
Q4 		$28.3M Sell
32,225
-371
-1% -$306K 2.71% 12
2023
Q3 		$26.8M Sell
32,596
-295
-0.9% -$232K 2.75% 11
2023
Q2 		$23.6M Sell
32,891
-120
-0.4% -$92.5K 2.29% 15
2023
Q1 		$27.1M Sell
33,011
-155
-0.5% -$117K 2.76% 9
2022
Q4 		$23.9M Sell
33,166
-994
-3% -$733K 2.62% 11
2022
Q3 		$23.5M Sell
34,160
-358
-1% -$225K 2.2% 12
2022
Q2 		$20.4M Buy
34,518
+31
+0.1% +$20.1K 1.8% 18
2022
Q1 		$24.1M Sell
34,487
-419
-1% -$265K 1.71% 19
2021
Q4 		$22M Buy
+34,906
New +$21.5M 1.49% 25

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Washington Trust Advisors's REGN Position: Q1 2026 in Review

Washington Trust Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q1 2026, selling an estimated $527K and leaving 28,735 shares worth $22.2M. The position accounts for 1.8% of the portfolio, ranked #14.

Washington Trust Advisors first reported a position in REGN in Q4 2021 and has held it in 18 quarters since. The position peaked at $31M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Washington Trust Advisors held 28,735 shares of Regeneron Pharmaceuticals worth $22.2M as of Q1 2026.
  • Washington Trust Advisors sold 689 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $527K.
  • Regeneron Pharmaceuticals made up 1.8% of Washington Trust Advisors's portfolio in Q1 2026, its #14 holding.
  • Washington Trust Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Washington Trust Advisors's Regeneron Pharmaceuticals position peaked at $31M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Washington Trust Advisors's 13F filing for Q1 2026, filed 6 Apr 2026.